2023-05-15 17:01:31 ET
- Evoke Pharma press release ( NASDAQ: EVOK ): Q1 GAAP EPS of -$0.67 misses by $0.09 .
- Revenue of $0.81M (+92.9% Y/Y) misses by $0.19M .
- As of March 31, 2023, cash and cash equivalents were approximately $8.2 million. We believe, based on our current operating plan, that our existing cash and cash equivalents, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the fourth quarter of 2023.
For further details see:
Evoke Pharma GAAP EPS of -$0.67 misses by $0.09, revenue of $0.81M misses by $0.19M